Please sign in to follow a disease.
Relapsed/refractory hematologic malignancies
Clinical trials for Relapsed/refractory hematologic malignancies explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory hematologic malignancies trials appear
Sign up with your email to follow new studies for Relapsed/refractory hematologic malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can engineered cells beat blood cancers that Won't quit?
Disease control Not yet recruitingThis early-phase trial tests an experimental cell therapy called iMagic Injection in adults with relapsed or refractory blood cancers, specifically B-cell non-Hodgkin lymphoma and multiple myeloma. Participants receive a single infusion of engineered immune cells designed to atta…
Matched conditions: RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
Disease control Not yet recruitingThis study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 pro…
Matched conditions: RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC